XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Operating activities    
Consolidated net (loss) income $ (3,760) $ 1,493
Less: Income from discontinued operations 6,700
Loss from continuing operations (3,760) (5,207)
Adjustments to reconcile consolidated net income (loss) to net cash used in operating activities    
Depreciation and amortization 17 22
Gain on sale of property and equipment (27)
Net unrealized loss on investments - Hedge Funds 166 127
Realized loss on investment in equity securities 46
Realized gain on available-for-sale securities (177) (15)
Amortization of discount on available-for-sale securities (519)
Impairment of investments - Other Pharmaceuticals 156
Realized gain in equity investments - Cyclo Therapeutics Inc. (424)
Unrealized loss in equity investments - Cyclo Therapeutics Inc. 2,124
Gain on dissolution of a business 18
Equity in loss of Day Three Labs Inc. 216
Bad debt expense 2
Stock-based compensation 649 1,180
Change in assets and liabilities, net of effects from discontinued operations:    
Trade accounts receivable (18) (28)
Interest receivable (33) (31)
Prepaid expenses and other current assets 796 566
Other assets (33) (28)
Accounts payable and accrued expenses (266) 1,017
Other current liabilities (908) 103
Due to related parties (3) (25)
Other liabilities 1 4
Net cash used in continuing operations (2,133) (2,159)
Net cash used in discontinued operations (421)
Net cash used in operating activities (2,133) (2,580)
Investing activities    
Purchases of available-for-sale securities (47,525) (57,119)
Proceeds from the sale and maturities of available-for-sale securities 47,462 22,922
Issuance of related party promissory note (250)
Proceeds from investments - Other Pharmaceuticals 42
Proceeds from sales of equity securities 271
Purchase of Investment in Cyclo Therapeutics Inc. (6,786)
Net cash used in investing activities of continuing operations (6,786) (34,197)
Proceeds from sale of 520 Property - discontinued operations 49,400
Payment of transaction costs for sale of 520 Property - discontinued operations (1,229)
Net cash provided by investing activities of discontinued operations 48,171
Net cash (used in) provided by investing activities (6,786) 13,974
Financing activities    
Payments for taxes related to shares withheld for employee taxes (39) (6)
Purchases of treasury stock (79)
Proceeds from sale of RMD membership units 925
Net cash provided by (used in) continuing operations 807 (6)
Payment of Note Payable in connection with sale of 520 Property - discontinued operations (15,000)
Net cash used in financing activities of discontinued operations (15,000)
Net cash provided by (used in) financing activities 807 (15,006)
Effect of exchange rate changes on cash and cash equivalents (189) (92)
Net decrease in cash and cash equivalents (8,301) (3,704)
Cash and cash equivalents, beginning of period 21,498 26,537
Cash and cash equivalents, end of period 13,197 22,833
Reconciliation of cash and restricted cash    
Cash and cash equivalents 13,197 22,173
Restricted cash 660
Total cash and cash equivalents and restricted cash shown in statement of cash flows 13,197 22,833
Non-cash supplemental disclosure    
Transaction costs related to sale of 520 Property included in accounts payable 43
Noncash consideration received in exchange for equipment 34
Withdrawal receivable from Hedge Funds included in other current assets $ 2,500,000